Annual report [Section 13 and 15(d), not S-K Item 405]

Accounts Payable and Accrued Expenses (Details)

v3.25.1
Accounts Payable and Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Accounts Payable and Accrued Expenses    
Accounts payable $ 7,464 $ 6,322
Accrued research and development 330 4,118
Accrued compensation 93 2,838
Other 1,599 739
Total accounts payable and accrued expenses 9,486 $ 14,017
Accrued consideration for the uBriGene Asset Purchase Agreement $ 1,300